| Budget Amount *help |
¥5,200,000 (Direct Cost: ¥4,000,000、Indirect Cost: ¥1,200,000)
Fiscal Year 2020: ¥650,000 (Direct Cost: ¥500,000、Indirect Cost: ¥150,000)
Fiscal Year 2019: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2018: ¥650,000 (Direct Cost: ¥500,000、Indirect Cost: ¥150,000)
Fiscal Year 2017: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2016: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
|
|---|
| Outline of Final Research Achievements |
As a first step to investigate preventive effects of orexin antagonists for delirium in critically ill patients, we measured the orexin levels in the cerebrospinal fluid and obtained results suggesting the possibility of a disappearance of diurnal variation in orexin secretion in delirious patients. We utilized existing simple sleep monitors to investigate the feasibility of simple sleep monitoring in critically ill patients and showed its characteristics and limitations. We found methodological problems in observational studies regarding potential preventive effects on delirium with orexin antagonists, and suggested the possibility of no preventive effect. We conducted a multicenter prospective pre-post intervention study to verify the usefulness of a sleep promotion and delirium prevention protocol in the ICU including orexin antagonists, but no significant results were obtained.
|
